2016 annual financial data
Halozyme Therapeutics 2016 Operating margin
Halozyme Therapeutics 2016 operating margin with verified reported values.
Direct answer
Operating margin was -56.72%.
Operating income was -83,210,000 USD and net income was -103,023,000 USD.
Operating cash flow was -50,383,000 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 146,691,000 USD
- Operating income
- -83,210,000 USD
- Net income
- -103,023,000 USD
- Operating cash flow
- -50,383,000 USD